SAN FRANCISCO, Sept. 18 DiObex, Inc., a privately heldbiotechnology company focused on the development of therapeutics to treatmetabolic diseases, announced today that CEO David Cory will deliver acorporate presentation at the upcoming Biotechnology Industry Organization(BIO) Mid-America Venture Forum in Milwaukee, Wisconsin. The DiObexpresentation will take place on Wednesday, September 26th at 1:30 p.m. at theHyatt Regency Hotel in Room A.
DiObex, Inc. is a San Francisco-based biotechnology company founded todevelop novel products for the treatment of metabolic diseases. DiObex hastwo product candidates in Phase 2 clinical development. DIO-901 (very lowdose glucagon) is in development as an extended release subcutaneousformulation for reducing or preventing insulin-induced hypoglycemia in type 1diabetes mellitus. DIO-901 has received Fast Track status from the Food andDrug Administration. DIO-902 (levdexketoconazole) is a novel cortisolsynthesis inhibitor in development for type 2 diabetes mellitus.Abnormalities in cortisol activity may play an important role in thedevelopment of metabolic syndrome, a constellation of conditions that placepeople at high risk for type 2 diabetes mellitus and cardiovascular disease.For more information, visit http://www.diobex.com.
SOURCE DiObex, Inc.